Last update 07 Jun 2025

Bevacizumab biosimilar(Boehringer)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
BI 695502, BI-695502
Target
Action
inhibitors
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
License Organization-
Drug Highest PhasePendingPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Colorectal CarcinomaPhase 3
United States
08 Jun 2016
Metastatic Colorectal CarcinomaPhase 3
Japan
08 Jun 2016
Metastatic Colorectal CarcinomaPhase 3
Spain
08 Jun 2016
Metastatic Colorectal CarcinomaPhase 3
Ukraine
08 Jun 2016
Advanced Lung Non-Small Cell CarcinomaPhase 3
United States
08 Jul 2015
Advanced Lung Non-Small Cell CarcinomaPhase 3
Japan
08 Jul 2015
Advanced Lung Non-Small Cell CarcinomaPhase 3
Argentina
08 Jul 2015
Advanced Lung Non-Small Cell CarcinomaPhase 3
Brazil
08 Jul 2015
Advanced Lung Non-Small Cell CarcinomaPhase 3
Bulgaria
08 Jul 2015
Advanced Lung Non-Small Cell CarcinomaPhase 3
Chile
08 Jul 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
663
Chemotherapy+BI 695502
egcfhjkqjn(psuezatrpq) = dnoxmkcbsp ehnxgoofdu (odhjtwqvgu )
Similar
28 Oct 2021
Chemotherapy+bevacizumab
egcfhjkqjn(psuezatrpq) = hsaifdkgkx ehnxgoofdu (odhjtwqvgu )
Phase 3
671
bblaoepkqi = plrwddeiin dwdqwpllwb (mfwmwkwxqv, slgatgjksv - hptalagxem)
-
13 Jan 2020
Phase 3
123
mFOLFOX6+BI 695502
btfrsebxha = gfgidmlaoz oixcoryvqy (inlicbdyre, sjcdtzsdix - psiwnsgajs)
-
21 Nov 2019
Phase 1
-
91
(BI 695502 (T))
tdciaabwqp(lpmcaknjie) = lbugisefiq cfcgfbcyhc (iacckoxrfr, 19.52)
-
08 Nov 2019
(United States (US)-Licensed Avastin® (R1))
tdciaabwqp(lpmcaknjie) = wbnawkymnb cfcgfbcyhc (iacckoxrfr, 15.57)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free